A computational model of induced pluripotent stem-cell derived cardiomyocytes for high throughput risk stratification of KCNQ1 genetic variants

In the last decade, there has been tremendous progress in identifying genetic anomalies linked to clinical disease. New experimental platforms have connected genetic variants to mechanisms underlying disruption of cellular and organ behavior and the emergence of proarrhythmic cardiac phenotypes. The development of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) signifies an important advance in the study of genetic disease in a patient-specific context. However, considerable limitations of iPSC-CM technologies have not been addressed: 1) phenotypic variability in apparently identical genotype perturbations, 2) low-throughput electrophysiological measurements, and 3) an immature phenotype which may impact translation to adult cardiac response. We have developed a computational approach intended to address these problems. We applied our recent iPSC-CM computational model to predict the proarrhythmic risk of 40 KCNQ1 genetic variants. An IKs computational model was fit to experimental data for each mutation, and the impact of each mutation was simulated in a population of iPSC-CM models. Using a test set of 15 KCNQ1 mutations with known clinical long QT phenotypes, we developed a method to stratify the effects of KCNQ1 mutations based on proarrhythmic markers. We utilized this method to predict the severity of the remaining 25 KCNQ1 mutations with unknown clinical significance. Tremendous phenotypic variability was observed in the iPSC-CM model population following mutant perturbations. A key novelty is our reporting of the impact of individual KCNQ1 mutant models on adult ventricular cardiomyocyte electrophysiology, allowing for prediction of mutant impact across the continuum of aging. This serves as a first step toward translating predicted response in the iPSC-CM model to predicted response of the adult ventricular myocyte given the same genetic mutation. As a whole, this study presents a new computational framework that serves as a high throughput method to evaluate risk of genetic mutations based-on proarrhythmic behavior in phenotypically variable populations.

[1]  Jens Meiler,et al.  High-Throughput Functional Evaluation of KCNQ1 Decrypts Variants of Unknown Significance , 2018, Circulation. Genomic and precision medicine.

[2]  Ncbi.  National Center for Biotechnology Information , 2008 .

[3]  Y. Pinto,et al.  Long QT syndrome: beyond the causal mutation , 2013, The Journal of physiology.

[4]  T. V. van Veen,et al.  The immature electrophysiological phenotype of iPSC‐CMs still hampers in vitro drug screening: Special focus on IK1 , 2017, Pharmacology & therapeutics.

[5]  Oliver J. Britton,et al.  Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity , 2017, Front. Physiol..

[6]  Jamie D. Kapplinger,et al.  Using the genome aggregation database, computational pathogenicity prediction tools, and patch clamp heterologous expression studies to demote previously published long QT syndrome type 1 mutations from pathogenic to benign. , 2017, Heart rhythm.

[7]  S. Priori,et al.  Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. , 2005, JAMA.

[8]  M. Sanguinetti,et al.  Compound Mutations: A Common Cause of Severe Long-QT Syndrome , 2004, Circulation.

[9]  Thomas O'Hara,et al.  Arrhythmia formation in subclinical ("silent") long QT syndrome requires multiple insults: quantitative mechanistic study using the KCNQ1 mutation Q357R as example. , 2012, Heart rhythm.

[10]  D. Sinnecker,et al.  Modeling Long-QT Syndromes with iPS Cells , 2013, Journal of Cardiovascular Translational Research.

[11]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[12]  P. Schwartz,et al.  The genetics underlying acquired long QT syndrome: impact for genetic screening. , 2016, European heart journal.

[13]  D. Tester,et al.  Long QT syndrome type 5-Lite: Defining the clinical phenotype associated with the potentially proarrhythmic p.Asp85Asn-KCNE1 common genetic variant. , 2018, Heart rhythm.

[14]  I. Karakikes,et al.  Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. , 2015, Circulation research.

[15]  Michael P Snyder,et al.  iPSC-derived cardiomyocytes reveal abnormal TGFβ signaling in left ventricular non-compaction cardiomyopathy , 2016, Nature Cell Biology.

[16]  A. Tanskanen,et al.  Voltage noise influences action potential duration in cardiac myocytes. , 2007, Mathematical biosciences.

[17]  Jamie D. Kapplinger,et al.  KCNQ1 p.L353L affects splicing and modifies the phenotype in a founder population with long QT syndrome type 1 , 2017, Journal of Medical Genetics.

[18]  Stuart A Cook,et al.  Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes , 2015, Stem Cell Research & Therapy.

[19]  Qinlian Zhou,et al.  Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells. , 2013, Heart rhythm.

[20]  Jingqi Q X Gong,et al.  Quantitative analysis of variability in an integrated model of human ventricular electrophysiology and β-adrenergic signaling. , 2020, Journal of molecular and cellular cardiology.

[21]  Shinya Yamanaka,et al.  Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications , 2017, Circulation research.

[22]  C. Clancy,et al.  In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome. , 2015, Journal of molecular and cellular cardiology.

[23]  S. Yamanaka,et al.  The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. , 2009, Biochemical and biophysical research communications.

[24]  Michael Krawczak,et al.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease , 2013, Human Genetics.

[25]  A. Glazer,et al.  Patient-independent human induced pluripotent stem cell model: A new tool for rapid determination of genetic variant pathogenicity in long QT syndrome. , 2019, Heart rhythm.

[26]  Michael J Ackerman,et al.  Genetics of long QT syndrome. , 2014, Methodist DeBakey cardiovascular journal.

[27]  Ye Chen-Izu,et al.  A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current , 2015, The Journal of physiology.

[28]  Kevin Burrage,et al.  Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm , 2016, Progress in biophysics and molecular biology.

[29]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Leppert,et al.  The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. , 1992, The New England journal of medicine.

[31]  V. Cameron,et al.  Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome. , 2014, Heart rhythm.

[32]  C. Sanders,et al.  Mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations , 2017, Science Advances.

[33]  Michael J Ackerman,et al.  The Promise and Peril of Precision Medicine: Phenotyping Still Matters Most. , 2016, Mayo Clinic proceedings.

[34]  Y Rudy,et al.  Cellular arrhythmogenic effects of congenital and acquired long-QT syndrome in the heterogeneous myocardium. , 2000, Circulation.

[35]  P. Schwartz,et al.  NOS1AP Is a Genetic Modifier of the Long-QT Syndrome , 2009, Circulation.

[36]  Yoram Rudy,et al.  Local control of β-adrenergic stimulation: Effects on ventricular myocyte electrophysiology and Ca(2+)-transient. , 2011, Journal of molecular and cellular cardiology.

[37]  Stefano Severi,et al.  A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. , 2015, Cardiovascular research.

[38]  E. Sobie,et al.  Population-based mechanistic modeling allows for quantitative predictions of drug responses across cell types , 2017, npj Systems Biology and Applications.

[39]  G. Vincent,et al.  Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations , 2008, BMC Medical Genetics.

[40]  Michael Eldar,et al.  Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations , 2015, Journal of cellular and molecular medicine.

[41]  David G Strauss,et al.  Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  P. Coumel,et al.  KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. , 1997, Circulation.

[43]  Michael P Snyder,et al.  Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. , 2016, Cell stem cell.

[44]  M. Ackerman,et al.  Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. , 2013, Translational research : the journal of laboratory and clinical medicine.

[45]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[46]  E. Sobie,et al.  Improved Prediction of Drug‐Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms , 2016, Clinical pharmacology and therapeutics.

[47]  Yasunari Kanda,et al.  Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs. , 2017, Journal of pharmacological sciences.

[48]  S. Priori,et al.  A recessive variant of the Romano-Ward long-QT syndrome? , 1998, Circulation.

[49]  R. Nussbaum,et al.  Functional phenotype variations of two novel KV7.1 mutations identified in patients with Long QT syndrome , 2020, Pacing and clinical electrophysiology : PACE.

[50]  P. Ellinor,et al.  Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. , 2009, Heart Rhythm.

[51]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[52]  Yuta Yamamoto,et al.  Phenotype-Based High-Throughput Classification of Long QT Syndrome Subtypes Using Human Induced Pluripotent Stem Cells , 2019, Stem cell reports.

[53]  Priyanka Garg,et al.  A computational model of induced pluripotent stem‐cell derived cardiomyocytes incorporating experimental variability from multiple data sources , 2019, The Journal of physiology.

[54]  Yan Zhuge,et al.  Induced Pluripotent Stem Cell – Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome , 2016 .

[55]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[56]  Haibo Ni,et al.  A Heart for Diversity: Simulating Variability in Cardiac Arrhythmia Research , 2018, Front. Physiol..

[57]  Ronald A. Li,et al.  Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy , 2015, Nature Communications.

[58]  Marco Perez,et al.  Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant. , 2018, Journal of the American College of Cardiology.

[59]  E. Kaufman,et al.  Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. , 2013, Heart rhythm.

[60]  Stefan A. Mann,et al.  Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes. , 2016, Journal of molecular and cellular cardiology.

[61]  Yoram Rudy,et al.  Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation , 2011, PLoS Comput. Biol..

[62]  Donald M Bers,et al.  Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity , 2013, Circulation.

[63]  Yolan J. Reckman,et al.  Variants in the 3′ untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner , 2011, European heart journal.

[64]  Russ B Altman,et al.  Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity , 2016, Nature Medicine.

[65]  T. Neumann,et al.  Influence of genetic modifiers on sudden cardiac death cases , 2018, International Journal of Legal Medicine.

[66]  S. Priori,et al.  Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.

[67]  S. Severi,et al.  Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach , 2017, Heart rhythm.

[68]  B. Rodríguez,et al.  Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology , 2013, Proceedings of the National Academy of Sciences.

[69]  E. Kaufman,et al.  Location of Mutation in the KCNQ1 and Phenotypic Presentation of Long QT Syndrome , 2003, Journal of cardiovascular electrophysiology.

[70]  G. Breithardt,et al.  Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients , 2004, Journal of Molecular Medicine.

[71]  D. Tester,et al.  Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. , 2005, Heart rhythm.

[72]  P. C. Viswanathan,et al.  Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.